Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.

Glucose-dependent insulinotropic polypeptide regulates body weight and food intake via GABAergic neurons in mice

Open access

Abstract

The development of single-molecule co-agonists for the glucagon-like peptide-1 (GLP-1) receptor (GLP-1R) and glucose-dependent insulinotropic polypeptide (GIP) receptor (GIPR) is considered a breakthrough in the treatment of obesity and type 2 diabetes. But although GIPR–GLP-1R co-agonism decreases body weight with superior efficacy relative to GLP-1R agonism alone in preclinical 1–3 and clinical studies 4,5 , the role of GIP in regulating energy metabolism remains enigmatic. Increasing evidence suggests that long-acting GIPR agonists act in the brain to decrease body weight through the inhibition of food intake 3,6–8 ; however, the mechanisms and neuronal populations through which GIP affects metabolism remain to be identified. Here, we report that long-acting GIPR agonists and GIPR–GLP-1R co-agonists decrease body weight and food intake via inhibitory GABAergic neurons. We show that acyl-GIP decreases body weight and food intake in male diet-induced obese wild-type mice, but not in mice with deletion of Gipr in Vgat (also known as Slc32a1 )-expressing GABAergic neurons ( Vgat-Gipr knockout). Whereas the GIPR–GLP-1R co-agonist MAR709 leads, in male diet-induced obese wild-type mice, to greater weight loss and further inhibition of food intake relative to a pharmacokinetically matched acyl-GLP-1 control, this superiority over GLP-1 vanishes in Vgat-Gipr knockout mice. Our data demonstrate that long-acting GIPR agonists crucially depend on GIPR signaling in inhibitory GABAergic neurons to decrease body weight and food intake.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s42255-023-00931-7

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Metabolic characterization of HFD-fed Vgat-Gipr KO mice. a–c, Body weight development (a) and body composition of 35-week-old male C57BL/6J wild-type (WT) and Vgat-Gipr knockout (KO) mice (n = 7–8 each group) (b,c). d–f, Food intake in 35-week-old male C57BL/6J mice (n = 7 each group) (d) as well as assimilated energy and assimilation efficiency in 35-week-old male C57BL/6J mice (n = 7–8 each group) (e,f). g–j, Respiratory exchange ratio (RER) (g), fatty acid (FA) oxidation (h), energy expenditure (i) and locomotor activity (j) in 35-week-old male C57BL/6J mice (n = 7–8 each group). k,l, Fasting levels of blood glucose (k) and insulin (l) in 37-week-old male C57BL/6J mice (n = 7–8 each group). m–p, Intraperitoneal insulin tolerance in 38-week-old male C57BL/6J mice (n = 7–8 each group) (m,n) and glucose tolerance in 34-week-old male C57BL/6J mice (o,p). q–t, HbA1c (q) and plasma levels of triglycerides (r), cholesterol (s) and free fatty acids (FFA) (t) in 40-week-old male C57BL/6J mice (n = 7–8 each group). Data in a,d,m–p were analyzed by repeated measures two-way analysis of variance (ANOVA) with Bonferroni’s post hoc test for comparison of individual time points. Data in b,c,e–h,j,k,l,q–t were analyzed using a Student’s two-sided, two-tailed t-test. Data in i were analyzed using ANCOVA with body weight as covariate. Date are mean ± s.e.m.; *P < 0.05; **P < 0.01 and ***P < 0.001. Individual P values are shown in the Source Data file, unless P < 0.0001. Source data
Fig. 1 Metabolic characterization of HFD-fed Vgat-Gipr KO mice. a–c, Body weight development (a) and body composition of 35-week-old male C57BL/6J wild-type (WT) and Vgat-Gipr knockout (KO) mice (n = 7–8 each group) (b,c). d–f, Food intake in 35-week-old male C57BL/6J mice (n = 7 each group) (d) as well as assimilated energy and assimilation efficiency in 35-week-old male C57BL/6J mice (n = 7–8 each group) (e,f). g–j, Respiratory exchange ratio (RER) (g), fatty acid (FA) oxidation (h), energy expenditure (i) and locomotor activity (j) in 35-week-old male C57BL/6J mice (n = 7–8 each group). k,l, Fasting levels of blood glucose (k) and insulin (l) in 37-week-old male C57BL/6J mice (n = 7–8 each group). m–p, Intraperitoneal insulin tolerance in 38-week-old male C57BL/6J mice (n = 7–8 each group) (m,n) and glucose tolerance in 34-week-old male C57BL/6J mice (o,p). q–t, HbA1c (q) and plasma levels of triglycerides (r), cholesterol (s) and free fatty acids (FFA) (t) in 40-week-old male C57BL/6J mice (n = 7–8 each group). Data in a,d,m–p were analyzed by repeated measures two-way analysis of variance (ANOVA) with Bonferroni’s post hoc test for comparison of individual time points. Data in b,c,e–h,j,k,l,q–t were analyzed using a Student’s two-sided, two-tailed t-test. Data in i were analyzed using ANCOVA with body weight as covariate. Date are mean ± s.e.m.; *P < 0.05; **P < 0.01 and ***P < 0.001. Individual P values are shown in the Source Data file, unless P < 0.0001. Source dataCC BY · PubMed Central
Fig. 2 Metabolic characterization of chow-fed Vgat-Gipr KO mice. a–c, Body weight development (n = 9–10 each group) (a) and body composition (n = 8–10 each group) of 36-week-old male C57BL/6J WT and Vgat-Gipr KO mice (b,c). d–f, Food intake in 36-week-old male C57BL/6J mice (n = 8–10 each group) (d) as well as assimilated energy and assimilation efficiency in 36-week-old male C57BL/6J mice (n = 8 each group) (e,f). g–j, RER (g), fatty acid oxidation (h), locomotor activity (i) and energy expenditure (j) in 36-week-old male C57BL/6J mice (n = 8 each group). k,l, Fasting levels of blood glucose (k) and insulin (l) in 38-week-old male C57BL/6J mice (n = 9–10 each group).m,n, Glucose tolerance in 38-week-old male C57BL/6J mice (n = 9–10 each group) (m) and insulin tolerance (n) in 39-week-old male C57BL/6J mice (n = 8–10 each group). o,p, Ad libitum plasma levels of triglycerides (o) and cholesterol (p) in 40-week-old male C57BL/6J mice (n = 9–10 each group). Data in a,d,m,n were analyzed by repeated measures two-way ANOVA with Bonferroni’s post hoc test for comparison of individual time points. Data in b,c,e–i,k,l,o,p were analyzed using a Student’s two-tailed t-test. Data in j were analyzed using ANCOVA with body weight as covariate. Cumulative food intake in d was assessed per cage in n = 8–10 double-housed mice. Date are mean ± s.e.m.; *P < 0.05; **P < 0.01 and ***P < 0.001. Individual P values are shown in the Source Data file, unless P < 0.0001. Source data
Fig. 2 Metabolic characterization of chow-fed Vgat-Gipr KO mice. a–c, Body weight development (n = 9–10 each group) (a) and body composition (n = 8–10 each group) of 36-week-old male C57BL/6J WT and Vgat-Gipr KO mice (b,c). d–f, Food intake in 36-week-old male C57BL/6J mice (n = 8–10 each group) (d) as well as assimilated energy and assimilation efficiency in 36-week-old male C57BL/6J mice (n = 8 each group) (e,f). g–j, RER (g), fatty acid oxidation (h), locomotor activity (i) and energy expenditure (j) in 36-week-old male C57BL/6J mice (n = 8 each group). k,l, Fasting levels of blood glucose (k) and insulin (l) in 38-week-old male C57BL/6J mice (n = 9–10 each group).m,n, Glucose tolerance in 38-week-old male C57BL/6J mice (n = 9–10 each group) (m) and insulin tolerance (n) in 39-week-old male C57BL/6J mice (n = 8–10 each group). o,p, Ad libitum plasma levels of triglycerides (o) and cholesterol (p) in 40-week-old male C57BL/6J mice (n = 9–10 each group). Data in a,d,m,n were analyzed by repeated measures two-way ANOVA with Bonferroni’s post hoc test for comparison of individual time points. Data in b,c,e–i,k,l,o,p were analyzed using a Student’s two-tailed t-test. Data in j were analyzed using ANCOVA with body weight as covariate. Cumulative food intake in d was assessed per cage in n = 8–10 double-housed mice. Date are mean ± s.e.m.; *P < 0.05; **P < 0.01 and ***P < 0.001. Individual P values are shown in the Source Data file, unless P < 0.0001. Source dataCC BY · PubMed Central
Fig. 3 Acyl-GIP effects on cFos neuronal activation in the hindbrain and acute food intake in HFD-fed Vgat-Gipr KO mice. a–c, Representative image (a) and quantification (b,c) of cFos-positive neurons, as well as fluorescently (Cy5)-labeled drug appearance, in the area postrema (AP) and NTS of 52-week-old C57BL/6J WT mice treated with a single subcutaneous bolus (150 nmol kg−1) of either acyl-GLP-1Cy5 or acyl-GIPCy5 (n = 3–4 mice each group). DAPI, 4,6-diamidino-2-phenylindole. d,e, Representative image (d) and quantification (e) of cFos-positive neurons, as well as Cy5-labeled drug appearance, in the area postrema of 26-week-old male C57BL/6J WT and Vgat-Gipr KO mice treated with a single subcutaneous dose of either vehicle or acyl-GIPCy5 (150 nmol kg−1; n = 4–5 each group) (d). f,g, Cumulative food intake in 35-week-old male C57BL/6J WT (f) and Vgat-Gipr KO (g) mice treated with a single subcutaneous dose of either vehicle or acyl-GIP (100 nmol kg−1, n = 7 each group). h,i, Cumulative food intake in 40-week-old female C57BL/6J WT (h) and Vgat-Gipr KO (i) mice treated with a single subcutaneous dose of either vehicle or acyl-GIP (100 nmol kg−1, n = 6–10 each group). Data in b,c,e were analyzed using an ordinary one-way ANOVA. Data in f–i were analyzed using repeated measures two-way ANOVA and a Bonferroni multiple comparison test for individual time points. Scale bars, 100 μm. Data are mean ± s.e.m.; NS, not significant; *P < 0.05; **P < 0.01 and ***P < 0.001. Individual P values are shown in the Source Data file, unless P < 0.0001. Source data
Fig. 3 Acyl-GIP effects on cFos neuronal activation in the hindbrain and acute food intake in HFD-fed Vgat-Gipr KO mice. a–c, Representative image (a) and quantification (b,c) of cFos-positive neurons, as well as fluorescently (Cy5)-labeled drug appearance, in the area postrema (AP) and NTS of 52-week-old C57BL/6J WT mice treated with a single subcutaneous bolus (150 nmol kg−1) of either acyl-GLP-1Cy5 or acyl-GIPCy5 (n = 3–4 mice each group). DAPI, 4,6-diamidino-2-phenylindole. d,e, Representative image (d) and quantification (e) of cFos-positive neurons, as well as Cy5-labeled drug appearance, in the area postrema of 26-week-old male C57BL/6J WT and Vgat-Gipr KO mice treated with a single subcutaneous dose of either vehicle or acyl-GIPCy5 (150 nmol kg−1; n = 4–5 each group) (d). f,g, Cumulative food intake in 35-week-old male C57BL/6J WT (f) and Vgat-Gipr KO (g) mice treated with a single subcutaneous dose of either vehicle or acyl-GIP (100 nmol kg−1, n = 7 each group). h,i, Cumulative food intake in 40-week-old female C57BL/6J WT (h) and Vgat-Gipr KO (i) mice treated with a single subcutaneous dose of either vehicle or acyl-GIP (100 nmol kg−1, n = 6–10 each group). Data in b,c,e were analyzed using an ordinary one-way ANOVA. Data in f–i were analyzed using repeated measures two-way ANOVA and a Bonferroni multiple comparison test for individual time points. Scale bars, 100 μm. Data are mean ± s.e.m.; NS, not significant; *P < 0.05; **P < 0.01 and ***P < 0.001. Individual P values are shown in the Source Data file, unless P < 0.0001. Source dataCC BY · PubMed Central
Fig. 4 Effects of acyl-GIP, acyl-GLP-1 and MAR709 on body weight and glucose metabolism in HFD-fed Vgat-Gipr KO mice. a–c, Body weight development (a), placebo-corrected weight loss after 26 days of treatment (b), and food intake (c) of 38-week-old male C57BL/6J WT mice treated daily with vehicle (Vhcl), acyl-GIP (100 nmol kg−1) or 10 nmol kg−1 of either acyl-GLP-1 or MAR709 (n = 7–8 each group). d–j, Fat and lean tissue mass in 38-week-old male C57BL/6J WT mice (d,e), fasting levels of blood glucose and insulin in 38-week-old male C57BL/6J WT mice (f,g), glucose tolerance in 38-week-old male C57BL/6J WT mice (h), HOMA-IR in 38-week-old male WT mice (i) and plasma levels of triglycerides in 35-week-old male C57BL/6J WT mice (j) (n = 7–8 each group). k–m, Body weight development (k), placebo-corrected weight loss after 26 days of treatment (l) and food intake (m) of 35-week-old male C57BL/6J Vgat-Gipr KO mice treated daily with vehicle, acyl-GIP (100 nmol kg−1) or 10 nmol kg−1 of either acyl-GLP-1 or MAR709 (n = 7–8 each group). n–t, Fat and lean tissue mass in 35-week-old male C57BL/6J KO mice (n,o), fasting levels of blood glucose and insulin in 35-week-old male WT mice (p,q), glucose tolerance in 35-week-old male C57BL/6J WT mice (r), HOMA-IR in 35-week-old male WT mice (s) and plasma levels of triglycerides in 35-week-old male C57BL/6J WT mice (t) (n = 7–8 mice each group). Data in a,h,k,r were analyzed using repeated measures two-way ANOVA and with Bonferroni post hoc comparison for individual time points. Data in c,m were analyzed using Fishers LSD test. Data in b,d–g,i,j,l,n–q,s,t were analyzed using ordinary one-way ANOVA. Data in g,i were analyzed using a Student’s two-tailed t-test. Food intake in c,m was assessed per cage in double-housed mice. Cages with mice shredding food were excluded from the analysis. Data area mean ± s.e.m.; NS, not significant; *P < 0.05; **P < 0.01 and ***P < 0.001. Individual P values are shown in the Source Data file, unless P < 0.0001. Source data
Fig. 4 Effects of acyl-GIP, acyl-GLP-1 and MAR709 on body weight and glucose metabolism in HFD-fed Vgat-Gipr KO mice. a–c, Body weight development (a), placebo-corrected weight loss after 26 days of treatment (b), and food intake (c) of 38-week-old male C57BL/6J WT mice treated daily with vehicle (Vhcl), acyl-GIP (100 nmol kg−1) or 10 nmol kg−1 of either acyl-GLP-1 or MAR709 (n = 7–8 each group). d–j, Fat and lean tissue mass in 38-week-old male C57BL/6J WT mice (d,e), fasting levels of blood glucose and insulin in 38-week-old male C57BL/6J WT mice (f,g), glucose tolerance in 38-week-old male C57BL/6J WT mice (h), HOMA-IR in 38-week-old male WT mice (i) and plasma levels of triglycerides in 35-week-old male C57BL/6J WT mice (j) (n = 7–8 each group). k–m, Body weight development (k), placebo-corrected weight loss after 26 days of treatment (l) and food intake (m) of 35-week-old male C57BL/6J Vgat-Gipr KO mice treated daily with vehicle, acyl-GIP (100 nmol kg−1) or 10 nmol kg−1 of either acyl-GLP-1 or MAR709 (n = 7–8 each group). n–t, Fat and lean tissue mass in 35-week-old male C57BL/6J KO mice (n,o), fasting levels of blood glucose and insulin in 35-week-old male WT mice (p,q), glucose tolerance in 35-week-old male C57BL/6J WT mice (r), HOMA-IR in 35-week-old male WT mice (s) and plasma levels of triglycerides in 35-week-old male C57BL/6J WT mice (t) (n = 7–8 mice each group). Data in a,h,k,r were analyzed using repeated measures two-way ANOVA and with Bonferroni post hoc comparison for individual time points. Data in c,m were analyzed using Fishers LSD test. Data in b,d–g,i,j,l,n–q,s,t were analyzed using ordinary one-way ANOVA. Data in g,i were analyzed using a Student’s two-tailed t-test. Food intake in c,m was assessed per cage in double-housed mice. Cages with mice shredding food were excluded from the analysis. Data area mean ± s.e.m.; NS, not significant; *P < 0.05; **P < 0.01 and ***P < 0.001. Individual P values are shown in the Source Data file, unless P < 0.0001. Source dataCC BY · PubMed Central
Extended Data Fig. 1 Tissue-selective expression of Gipr in wild-type and Vgat-Gipr Ko mice. Expression of Gipr in hypothalamus (n = 7-8 each group) (a), hindbrain (n = 8 each group) (b), and pancreas (5-7 each group) of 40-wk old HFD-fed DIO male C57BL/6J wild-type and Vgat-Gipr KO mice (c). Expression of Gipr in pancreatic islets isolated from 12-wk old male C57BL/6J wild-type and Vgat-Gipr KO mice (d) and Gipr expression in epididymal white adipose tissue (eWAT) (n = 6-7 each group) of 40-wk old HFD-fed DIO male C57BL/6J wild-type and Vgat-Gipr KO mice (e). Expression of Gipr in sciatic nerve (n = 7-8 each group) (f), dorsal root ganglia (DRG) (n = 6-7 each group) (g), trigeminal ganglion (n = 7 each group) (h), as well as in duodenum (n = 7 each group) (i), jejunum (n = 8 each group) (j), ileum (n = 8 each group) (k), and colon (n = 8 each group) (l) of 12-wk old HFD-fed male C57BL/6J wild-type and Vgat-Gipr KO mice. Representative image of of insulin and glucagon immunostaining in pancreata of 38-wk old HFD-fed male C57BL/6J wild-type and Vgat-Gipr KO mice (n = 5 each group) (m), and quantification of pancreatic islet area (n = 5 each group) (n), α-cell mass (n = 5 each group) (o), β-cell mass (n = 5 each group) (p), α-cell/β-cell mass ratio (n = 5 each group) (q), as well insulin area (n = 5 each group) (r) and glucagon area (n = 5 each group) (s) in 38-wk old male HFD-fed C57BL/6J wild-type and Vgat-Gipr KO mice. Data were analyzed using student’s 2-sided, two-tailed t-test. Data represent mean ± SEM. Asterisk indicates * p < 0.05. Individual p values are shown in the Data Source file. Source data
Extended Data Fig. 1 Tissue-selective expression of Gipr in wild-type and Vgat-Gipr Ko mice. Expression of Gipr in hypothalamus (n = 7-8 each group) (a), hindbrain (n = 8 each group) (b), and pancreas (5-7 each group) of 40-wk old HFD-fed DIO male C57BL/6J wild-type and Vgat-Gipr KO mice (c). Expression of Gipr in pancreatic islets isolated from 12-wk old male C57BL/6J wild-type and Vgat-Gipr KO mice (d) and Gipr expression in epididymal white adipose tissue (eWAT) (n = 6-7 each group) of 40-wk old HFD-fed DIO male C57BL/6J wild-type and Vgat-Gipr KO mice (e). Expression of Gipr in sciatic nerve (n = 7-8 each group) (f), dorsal root ganglia (DRG) (n = 6-7 each group) (g), trigeminal ganglion (n = 7 each group) (h), as well as in duodenum (n = 7 each group) (i), jejunum (n = 8 each group) (j), ileum (n = 8 each group) (k), and colon (n = 8 each group) (l) of 12-wk old HFD-fed male C57BL/6J wild-type and Vgat-Gipr KO mice. Representative image of of insulin and glucagon immunostaining in pancreata of 38-wk old HFD-fed male C57BL/6J wild-type and Vgat-Gipr KO mice (n = 5 each group) (m), and quantification of pancreatic islet area (n = 5 each group) (n), α-cell mass (n = 5 each group) (o), β-cell mass (n = 5 each group) (p), α-cell/β-cell mass ratio (n = 5 each group) (q), as well insulin area (n = 5 each group) (r) and glucagon area (n = 5 each group) (s) in 38-wk old male HFD-fed C57BL/6J wild-type and Vgat-Gipr KO mice. Data were analyzed using student’s 2-sided, two-tailed t-test. Data represent mean ± SEM. Asterisk indicates * p < 0.05. Individual p values are shown in the Data Source file. Source dataCC BY · PubMed Central
Extended Data Fig. 2 Tissue histology and hypothalamic target gene expression in DIO wild-type and Vgat-Gipr KO mice. Ad libitum plasma levels of GLP-1total (a) and GIPtotal (b) in 40-wk old male C57BL/6J DIO wild-type and Vgat-Gipr KO mice mice (n = 7-8 each group). Serum levels of leptin in 40-wk old male C57BL/6J DIO wild-type and Vgat-Gipr KO mice (n = 6-7 each group) (c), representative H&E staining of liver and inguinal white adipose tissue (iWAT) in 40-wk old C57BL/6J mice (n = 7-8 each group, scale bar: 100μm) (d), corresponding steatosis score (n = 7-8 each group) (e) and mean iWAT adipocyte size (n = 7 each group) (f), as well as hypothalamic expression of proopiomelanocortin; Pomc (n = 7 each group) (g), cocaine and amphetamine regulated transcript; Cart (n = 7-8 each group) (h), neuropeptide y; Npy (n = 7 each group) (i), agouti-related peptide; Agrp (n = 7 each group) (j), somatostatin; Sst (n = 7 each group) (k), arginine vasopressin; Avp (n = 7 each group) (l), tachykinin precursor 1; Tac1 (n = 7 each group) (m), parathyroid hormone like hormone; Pthlh (n = 7 each group) (n), amyloid beta precursor like protein 1; Aplp1 (n = 7 each group) (o) and cystacin c; Cst3 (n = 7 each group) (p) in 40-wk old male C57BL/6J DIO wild-type and Vgat-Gipr KO mice. Expression of cholescystokinin; Cck (q), GLP-1R (r), hypocretin neuropeptide precursor; Hcrt (s) and oxytocin; Oxt (t) in the hindbrain of 40-wk old male C57BL/6J DIO wild-type and Vgat-Gipr KO mice. Data were analyzed using student’s 2-sided, two-tailed t-test. Date represent mean ± SEM. Asterisks indicate * p < 0.05; ** p < 0.01 and *** p < 0.001. Individual p values are shown in the Data Source file. Source data
Extended Data Fig. 2 Tissue histology and hypothalamic target gene expression in DIO wild-type and Vgat-Gipr KO mice. Ad libitum plasma levels of GLP-1total (a) and GIPtotal (b) in 40-wk old male C57BL/6J DIO wild-type and Vgat-Gipr KO mice mice (n = 7-8 each group). Serum levels of leptin in 40-wk old male C57BL/6J DIO wild-type and Vgat-Gipr KO mice (n = 6-7 each group) (c), representative H&E staining of liver and inguinal white adipose tissue (iWAT) in 40-wk old C57BL/6J mice (n = 7-8 each group, scale bar: 100μm) (d), corresponding steatosis score (n = 7-8 each group) (e) and mean iWAT adipocyte size (n = 7 each group) (f), as well as hypothalamic expression of proopiomelanocortin; Pomc (n = 7 each group) (g), cocaine and amphetamine regulated transcript; Cart (n = 7-8 each group) (h), neuropeptide y; Npy (n = 7 each group) (i), agouti-related peptide; Agrp (n = 7 each group) (j), somatostatin; Sst (n = 7 each group) (k), arginine vasopressin; Avp (n = 7 each group) (l), tachykinin precursor 1; Tac1 (n = 7 each group) (m), parathyroid hormone like hormone; Pthlh (n = 7 each group) (n), amyloid beta precursor like protein 1; Aplp1 (n = 7 each group) (o) and cystacin c; Cst3 (n = 7 each group) (p) in 40-wk old male C57BL/6J DIO wild-type and Vgat-Gipr KO mice. Expression of cholescystokinin; Cck (q), GLP-1R (r), hypocretin neuropeptide precursor; Hcrt (s) and oxytocin; Oxt (t) in the hindbrain of 40-wk old male C57BL/6J DIO wild-type and Vgat-Gipr KO mice. Data were analyzed using student’s 2-sided, two-tailed t-test. Date represent mean ± SEM. Asterisks indicate * p < 0.05; ** p < 0.01 and *** p < 0.001. Individual p values are shown in the Data Source file. Source dataCC BY · PubMed Central
Extended Data Fig. 3 Metabolic characterization of female HFD-fed Vgat-Gipr KO mice. Body weight development (a), and body composition (b) of 40-wk old female HFD-fed C57BL/6J wild-type (WT) and Vgat-Gipr KO (KO) mice (WT/KO n = 10/6 mice). Cumulative food intake (d), as well as locomotor activity (e), fatty acid (FA) oxidation (f), respiratory exchange ratio (RER) (G) and energy expenditure (h) in 40-wk old female C57BL/6J mice (WT/KO n = 10/6 mice). Fasting plasma levels of blood glucose (i) and insulin (j) in 43-wk old female C57BL/6J mice (WT/KO n = 10/6 mice), intraperitoneal glucose tolerance in 42-wk old female C57BL/6J mice (WT/KO n = 10/6 mice) (k), intraperitoneal insulin tolerance in 42-wk old female C57BL/6J mice (WT/KO n = 9/6 mice) (l) and plasma levels HbA1c (m), triglycerides (n), cholesterol (o) and free fatty acids (p) in 44-wk old female C57BL/6J mice (WT/KO n = 10/6 mice). Data in panel A,D,K and L were analyzed by repeated measures 2-way ANOVA with Bonferroni’s post hoc test for comparison of individual time points. Data in panel B,C,E-G,I,J,M-P were analyzed using student’s 2-sided, two-tailed t-test. Data in panel H were analyzed using ANCOVA with body weight as covariate. Date represent means ± SEM; asterisks indicate * p < 0.05; ** p < 0.01 and *** p < 0.001. Individual p values are shown in the Data Source file. Source data
Extended Data Fig. 3 Metabolic characterization of female HFD-fed Vgat-Gipr KO mice. Body weight development (a), and body composition (b) of 40-wk old female HFD-fed C57BL/6J wild-type (WT) and Vgat-Gipr KO (KO) mice (WT/KO n = 10/6 mice). Cumulative food intake (d), as well as locomotor activity (e), fatty acid (FA) oxidation (f), respiratory exchange ratio (RER) (G) and energy expenditure (h) in 40-wk old female C57BL/6J mice (WT/KO n = 10/6 mice). Fasting plasma levels of blood glucose (i) and insulin (j) in 43-wk old female C57BL/6J mice (WT/KO n = 10/6 mice), intraperitoneal glucose tolerance in 42-wk old female C57BL/6J mice (WT/KO n = 10/6 mice) (k), intraperitoneal insulin tolerance in 42-wk old female C57BL/6J mice (WT/KO n = 9/6 mice) (l) and plasma levels HbA1c (m), triglycerides (n), cholesterol (o) and free fatty acids (p) in 44-wk old female C57BL/6J mice (WT/KO n = 10/6 mice). Data in panel A,D,K and L were analyzed by repeated measures 2-way ANOVA with Bonferroni’s post hoc test for comparison of individual time points. Data in panel B,C,E-G,I,J,M-P were analyzed using student’s 2-sided, two-tailed t-test. Data in panel H were analyzed using ANCOVA with body weight as covariate. Date represent means ± SEM; asterisks indicate * p < 0.05; ** p < 0.01 and *** p < 0.001. Individual p values are shown in the Data Source file. Source dataCC BY · PubMed Central
Extended Data Fig. 4 Sequence of the used GIP and GLP-1 analogs. Sequence of the used acyl-GIP, acyl-GLP-1, MAR709, acyl-GIPCy5 and acyl-GLP-1Cy5 (A).
Extended Data Fig. 4 Sequence of the used GIP and GLP-1 analogs. Sequence of the used acyl-GIP, acyl-GLP-1, MAR709, acyl-GIPCy5 and acyl-GLP-1Cy5 (A).CC BY · PubMed Central
Extended Data Fig. 5 Acyl-GIP effects on cFos neuronal activation in the hypothalamus in HFD-fed Vgat-Gipr KO mice. Representative image of hypothalamic acyl-GIPCy5 fluorescence (n = 3-5 each group) (a) and cFos neuronal activity in the arcuate nucleus (ARC), paraventricular nucleus (PVN), ventromedial hypothalamus (VMH) and dorsomedial hypothalamus (DMH) (n = 4-5 each group) (b) in 26-wk old male C57BL/6J wild-type (WT) and Vgat-Gipr (KO) mice treated subcutaneous (s.c.) with a single dose of either vehicle or acyl-GIPCy5 (150 nmol/kg; n = 3-5 each group). Corresponding cFos quantification in the ARC (n = 4-5 each group) (c), PVN (n = 4-5 each group) (d), VMH (n = 4-5 each group) (e), and DMH (n = 4-5 each group) (f). CFos neuronal activity (G) and corresponding cFos quantification (H) in the lateral parabrachial nucleus (LPBN) in 26-wk old male C57BL/6J WT and Vgat-Gipr (KO) mice treated s.c. with a single dose of either vehicle or acyl-GIPCy5 (150 nmol/kg; n = 4-5 each group). Data in panel C-F,H were analyzed using student’s 2-sided, 2-sided, 2-tailed t-test. Scale bars in panels A and B are 100 μm, scale bars in panel G are 200 μm. Data represent means ± SEM; asterisks indicate * p < 0.05. Individual p values are shown in the Data Source file. Source data
Extended Data Fig. 5 Acyl-GIP effects on cFos neuronal activation in the hypothalamus in HFD-fed Vgat-Gipr KO mice. Representative image of hypothalamic acyl-GIPCy5 fluorescence (n = 3-5 each group) (a) and cFos neuronal activity in the arcuate nucleus (ARC), paraventricular nucleus (PVN), ventromedial hypothalamus (VMH) and dorsomedial hypothalamus (DMH) (n = 4-5 each group) (b) in 26-wk old male C57BL/6J wild-type (WT) and Vgat-Gipr (KO) mice treated subcutaneous (s.c.) with a single dose of either vehicle or acyl-GIPCy5 (150 nmol/kg; n = 3-5 each group). Corresponding cFos quantification in the ARC (n = 4-5 each group) (c), PVN (n = 4-5 each group) (d), VMH (n = 4-5 each group) (e), and DMH (n = 4-5 each group) (f). CFos neuronal activity (G) and corresponding cFos quantification (H) in the lateral parabrachial nucleus (LPBN) in 26-wk old male C57BL/6J WT and Vgat-Gipr (KO) mice treated s.c. with a single dose of either vehicle or acyl-GIPCy5 (150 nmol/kg; n = 4-5 each group). Data in panel C-F,H were analyzed using student’s 2-sided, 2-sided, 2-tailed t-test. Scale bars in panels A and B are 100 μm, scale bars in panel G are 200 μm. Data represent means ± SEM; asterisks indicate * p < 0.05. Individual p values are shown in the Data Source file. Source dataCC BY · PubMed Central
Extended Data Fig. 6 Effects of acyl-GIP, acyl-GLP-1 and MAR709 on absolute body weight in HFD-fed Vgat-Gipr KO mice, and analysis of Vgat/Gipr in published scRNA repositories. Starting body weight (a) and body weight change (b) in 38-wk old male C57BL/6J wild-type (WT) or Vgat-Gipr KO mice treated daily with either Vehicle, acyl-GIP (100 nmolkg), or 10 nmol/kg of either acyl-GLP-1 or MAR709 (n = 7-8 each group). Cell types expressing Vgat and/or Gipr in the hypothalamus and dorsal vagal complex (DVC) (c). Distribution of cells co-expressing Gipr and Vgat within 7 clusters of GABAergic neurons identified in the DVC (d). Correlation plots with Pearson’s correlations between 7 clusters (GABA1-7) of GABAergic neurons in the DVC (e). UMAP of GABAergic neurons in the DVC colored by GABAergic neuron cluster, and expression of Vgat and Gipr in each cell, with the color corresponding to log-normalized UMI counts scaled to the maximum of each gene (f). The dot plot of the top 5 genes most associated with each GABAergic neuron population as determined by Wilcoxon-rank-sum test (g). Data in panel A were analyzed using ordinary 1-way ANOVA, data in panel B were analyzed using ordinary 1-way ANOVA and using Holm-Sidak multiple comparison test. Date represent means ± SEM; asterisks indicate * p < 0.05; ** p < 0.01 and *** p < 0.001. Individual p values are shown in the Data Source file, unless p < 0.0001. Data shown in panels C, D, E, F, G were generated based on publicly available snRNA Seq datasets of hypothalamus (Steuernagel et al.15) or DVC (Lugwig et al.17). Source data
Extended Data Fig. 6 Effects of acyl-GIP, acyl-GLP-1 and MAR709 on absolute body weight in HFD-fed Vgat-Gipr KO mice, and analysis of Vgat/Gipr in published scRNA repositories. Starting body weight (a) and body weight change (b) in 38-wk old male C57BL/6J wild-type (WT) or Vgat-Gipr KO mice treated daily with either Vehicle, acyl-GIP (100 nmolkg), or 10 nmol/kg of either acyl-GLP-1 or MAR709 (n = 7-8 each group). Cell types expressing Vgat and/or Gipr in the hypothalamus and dorsal vagal complex (DVC) (c). Distribution of cells co-expressing Gipr and Vgat within 7 clusters of GABAergic neurons identified in the DVC (d). Correlation plots with Pearson’s correlations between 7 clusters (GABA1-7) of GABAergic neurons in the DVC (e). UMAP of GABAergic neurons in the DVC colored by GABAergic neuron cluster, and expression of Vgat and Gipr in each cell, with the color corresponding to log-normalized UMI counts scaled to the maximum of each gene (f). The dot plot of the top 5 genes most associated with each GABAergic neuron population as determined by Wilcoxon-rank-sum test (g). Data in panel A were analyzed using ordinary 1-way ANOVA, data in panel B were analyzed using ordinary 1-way ANOVA and using Holm-Sidak multiple comparison test. Date represent means ± SEM; asterisks indicate * p < 0.05; ** p < 0.01 and *** p < 0.001. Individual p values are shown in the Data Source file, unless p < 0.0001. Data shown in panels C, D, E, F, G were generated based on publicly available snRNA Seq datasets of hypothalamus (Steuernagel et al.15) or DVC (Lugwig et al.17). Source dataCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

1 more claim about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 35 references

Cited by

See all 110

Metadata

Authors
Liskiewicz, A., Khalil, A., Liskiewicz, D., Novikoff, A., Grandl, G., Maity-Kumar, G., Gutgesell, R. M., Bakhti, M., Bastidas-Ponce, A., Czarnecki, O., Makris, K., Lickert, H., Feuchtinger, A., Tost, M., Coupland, C., Ständer, L., Akindehin, S., Prakash, S., Abrar, F., Castelino, R. L., He, Y., Knerr, P. J., Yang, B., Hogendorf, W. F. J., Zhang, S., Hofmann, S. M., Finan, B., DiMarchi, R. D., Tschöp, M. H., Douros, J. D., & Müller, T. D.
Affiliations
  • Helmholtz Munich (DE)
  • Indiana University Bloomington (US)
Corresponding author
Müller, Timo D.
Venue
Nature Metabolism
Published
2023-11-09
Volume
5
Issue
12
Pages
2075-2085
ISSN
2522-5812 (ISSN-L)
OpenAlex
W4388524094
Cited by
110
References
35
Citations by year
2026: 37 · 2025: 46 · 2024: 25 · 2023: 2
FWCI
16.35
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Metabolism (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion)
  • PuSH - Publication Server of Helmholtz Zentrum München (submittedVersion)
Funders
  • Deutsche Forschungsgemeinschaft (GRK2816/1, TRR- 152, SFB1123, RTG 2816, TRR296)
  • Helmholtz Zentrum München
  • H2020 European Research Council (695054)
  • HORIZON EUROPE European Research Council (101044445)
Topics
  • Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
Keywords
glucose-dependent insulinotropic polypeptide, GIP receptor, GLP-1 receptor, GABAergic neurons, vesicular GABA transporter, dietary intake, body weight regulation, diet-induced obesity, energy metabolism
MeSH terms
Animals, Diabetes Mellitus, Type 2, Eating, Gastric Inhibitory Polypeptide, Glucose, Male, Obesity, Receptors, G-Protein-Coupled, Mice, Glucagon-Like Peptide 1, GABAergic Neurons

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Glucose-dependent insulinotropic polypeptide regulates body weight and food intake via GABAergic neurons in mice. https://app.cochat.ai/papers/10.1038/s42255-023-00931-7
The paper
Liskiewicz, A., Khalil, A., Liskiewicz, D., Novikoff, A., Grandl, G., Maity-Kumar, G., Gutgesell, R. M., Bakhti, M., Bastidas-Ponce, A., Czarnecki, O., Makris, K., Lickert, H., Feuchtinger, A., Tost, M., Coupland, C., Ständer, L., Akindehin, S., Prakash, S., Abrar, F., . . . Müller, T. D. (2023). Glucose-dependent insulinotropic polypeptide regulates body weight and food intake via GABAergic neurons in mice. Nature Metabolism. https://doi.org/10.1038/s42255-023-00931-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.